A single-center pilot study showed that oral administration of pirfenidone, a small-molecule compound inhibiting TGFβ synthesis, significantly slowed the decline in renal function in patients with FSGS (275). This evidence concerns the gene TGFB1 and focal segmental glomerulosclerosis.